Novo Nordisk is embarking on significant transformations as it intends to eliminate 9,000 positions, aiming to achieve savings of around DKK8 billion (£1 billion) in yearly expenses. This choice signifies the peak of a demanding year for the Danish pharmaceutical company, as investor confidence has diminished due to multiple hurdles. These challenges encompass issues in […]
Read More